vs

Side-by-side financial comparison of CABOT CORP (CBT) and Verisign (VRSN). Click either name above to swap in a different company.

CABOT CORP is the larger business by last-quarter revenue ($849.0M vs $425.3M, roughly 2.0× Verisign). Verisign runs the higher net margin — 48.5% vs 8.6%, a 39.9% gap on every dollar of revenue. On growth, Verisign posted the faster year-over-year revenue change (7.6% vs -11.1%). Verisign produced more free cash flow last quarter ($285.1M vs $57.0M). Over the past eight quarters, Verisign's revenue compounded faster (5.2% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.

CBT vs VRSN — Head-to-Head

Bigger by revenue
CBT
CBT
2.0× larger
CBT
$849.0M
$425.3M
VRSN
Growing faster (revenue YoY)
VRSN
VRSN
+18.7% gap
VRSN
7.6%
-11.1%
CBT
Higher net margin
VRSN
VRSN
39.9% more per $
VRSN
48.5%
8.6%
CBT
More free cash flow
VRSN
VRSN
$228.1M more FCF
VRSN
$285.1M
$57.0M
CBT
Faster 2-yr revenue CAGR
VRSN
VRSN
Annualised
VRSN
5.2%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBT
CBT
VRSN
VRSN
Revenue
$849.0M
$425.3M
Net Profit
$73.0M
$206.2M
Gross Margin
24.9%
88.5%
Operating Margin
15.2%
67.0%
Net Margin
8.6%
48.5%
Revenue YoY
-11.1%
7.6%
Net Profit YoY
-21.5%
7.7%
EPS (diluted)
$1.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
VRSN
VRSN
Q4 25
$849.0M
$425.3M
Q3 25
$899.0M
$419.1M
Q2 25
$923.0M
$409.9M
Q1 25
$936.0M
$402.3M
Q4 24
$955.0M
$395.4M
Q3 24
$1.0B
$390.6M
Q2 24
$1.0B
$387.1M
Q1 24
$1.0B
$384.3M
Net Profit
CBT
CBT
VRSN
VRSN
Q4 25
$73.0M
$206.2M
Q3 25
$43.0M
$212.8M
Q2 25
$101.0M
$207.4M
Q1 25
$94.0M
$199.3M
Q4 24
$93.0M
$191.5M
Q3 24
$137.0M
$201.3M
Q2 24
$109.0M
$198.8M
Q1 24
$84.0M
$194.1M
Gross Margin
CBT
CBT
VRSN
VRSN
Q4 25
24.9%
88.5%
Q3 25
24.5%
88.4%
Q2 25
26.4%
88.0%
Q1 25
25.7%
87.7%
Q4 24
24.6%
87.8%
Q3 24
24.0%
88.0%
Q2 24
25.2%
87.8%
Q1 24
24.1%
87.2%
Operating Margin
CBT
CBT
VRSN
VRSN
Q4 25
15.2%
67.0%
Q3 25
15.2%
67.8%
Q2 25
18.1%
68.5%
Q1 25
17.3%
67.4%
Q4 24
16.2%
66.7%
Q3 24
15.0%
68.9%
Q2 24
16.9%
68.8%
Q1 24
15.3%
67.4%
Net Margin
CBT
CBT
VRSN
VRSN
Q4 25
8.6%
48.5%
Q3 25
4.8%
50.8%
Q2 25
10.9%
50.6%
Q1 25
10.0%
49.5%
Q4 24
9.7%
48.4%
Q3 24
13.7%
51.5%
Q2 24
10.7%
51.4%
Q1 24
8.2%
50.5%
EPS (diluted)
CBT
CBT
VRSN
VRSN
Q4 25
$1.37
Q3 25
$0.80
Q2 25
$1.86
Q1 25
$1.69
Q4 24
$1.67
Q3 24
$2.41
Q2 24
$1.94
Q1 24
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
VRSN
VRSN
Cash + ST InvestmentsLiquidity on hand
$230.0M
$580.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.6B
$-2.2B
Total Assets
$3.8B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
VRSN
VRSN
Q4 25
$230.0M
$580.5M
Q3 25
$258.0M
$617.7M
Q2 25
$239.0M
$593.8M
Q1 25
$213.0M
$648.5M
Q4 24
$183.0M
$599.9M
Q3 24
$223.0M
$644.9M
Q2 24
$197.0M
$689.9M
Q1 24
$206.0M
$924.7M
Total Debt
CBT
CBT
VRSN
VRSN
Q4 25
Q3 25
$1.1B
Q2 25
Q1 25
Q4 24
Q3 24
$1.1B
Q2 24
Q1 24
Stockholders' Equity
CBT
CBT
VRSN
VRSN
Q4 25
$1.6B
$-2.2B
Q3 25
$1.6B
$-2.1B
Q2 25
$1.5B
$-2.0B
Q1 25
$1.4B
$-2.0B
Q4 24
$1.4B
$-2.0B
Q3 24
$1.4B
$-1.9B
Q2 24
$1.3B
$-1.8B
Q1 24
$1.4B
$-1.6B
Total Assets
CBT
CBT
VRSN
VRSN
Q4 25
$3.8B
$1.3B
Q3 25
$3.8B
$1.4B
Q2 25
$3.8B
$1.4B
Q1 25
$3.8B
$1.4B
Q4 24
$3.6B
$1.4B
Q3 24
$3.7B
$1.5B
Q2 24
$3.6B
$1.5B
Q1 24
$3.6B
$1.7B
Debt / Equity
CBT
CBT
VRSN
VRSN
Q4 25
Q3 25
0.70×
Q2 25
Q1 25
Q4 24
Q3 24
0.75×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
VRSN
VRSN
Operating Cash FlowLast quarter
$126.0M
$289.6M
Free Cash FlowOCF − Capex
$57.0M
$285.1M
FCF MarginFCF / Revenue
6.7%
67.0%
Capex IntensityCapex / Revenue
8.1%
1.1%
Cash ConversionOCF / Net Profit
1.73×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$401.0M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
VRSN
VRSN
Q4 25
$126.0M
$289.6M
Q3 25
$219.0M
$307.7M
Q2 25
$249.0M
$202.5M
Q1 25
$73.0M
$291.3M
Q4 24
$124.0M
$231.5M
Q3 24
$204.0M
$253.4M
Q2 24
$207.0M
$160.4M
Q1 24
$176.0M
$257.3M
Free Cash Flow
CBT
CBT
VRSN
VRSN
Q4 25
$57.0M
$285.1M
Q3 25
$155.0M
$303.0M
Q2 25
$188.0M
$194.7M
Q1 25
$1.0M
$285.5M
Q4 24
$47.0M
$222.0M
Q3 24
$112.0M
$247.8M
Q2 24
$155.0M
$151.2M
Q1 24
$133.0M
$253.5M
FCF Margin
CBT
CBT
VRSN
VRSN
Q4 25
6.7%
67.0%
Q3 25
17.2%
72.3%
Q2 25
20.4%
47.5%
Q1 25
0.1%
71.0%
Q4 24
4.9%
56.1%
Q3 24
11.2%
63.4%
Q2 24
15.3%
39.1%
Q1 24
13.1%
66.0%
Capex Intensity
CBT
CBT
VRSN
VRSN
Q4 25
8.1%
1.1%
Q3 25
7.1%
1.1%
Q2 25
6.6%
1.9%
Q1 25
7.7%
1.4%
Q4 24
8.1%
2.4%
Q3 24
9.2%
1.4%
Q2 24
5.1%
2.4%
Q1 24
4.2%
1.0%
Cash Conversion
CBT
CBT
VRSN
VRSN
Q4 25
1.73×
1.40×
Q3 25
5.09×
1.45×
Q2 25
2.47×
0.98×
Q1 25
0.78×
1.46×
Q4 24
1.33×
1.21×
Q3 24
1.49×
1.26×
Q2 24
1.90×
0.81×
Q1 24
2.10×
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

VRSN
VRSN

Segment breakdown not available.

Related Comparisons